C4 Therapeutics Inc (CCCC) Stock Price, Quote & News

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BR...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 231 0700

Website: www.c4therapeutics.com

Address:

490 Arsenal Way, Suite120, Watertown, United States

LabPsycho Jun. 16 at 2:22 PM

$CCCC Molecular Dynamic Simulation of C4's CFT8919 drug (or something close to it). Shown is CFT8919 in complex with Cereblon, a component of the CRL4A E3 ubiquitin ligase complex and epidermal growth factor receptor (EGFR), mutated forms of which are thought to play a key role in lung and other cancers . 50k atoms, many billions of calculations and taking a > 1 gigabyte file down to a 3Mb Animated gif of the simulation shown below. For entertainment purposes only. See my post below for more info. Hopefully I will toss together a Youtube video for a more detailed explanation. Enjoy the view!

0 · Reply

jerzypawlik Jun. 13 at 9:22 PM

$CCCC Hello everyone. We had a very good day today. However I'm out temporarily. I sold all my shares today, and relocated money in new projects. I couldn't resist it, many good companies were beaten up today, so that created huge opportunities to jump in. I'm going to wait for pull back here, and start my position again. Don't worry everyone I'm still very positive on this company and will keep an eye in near future. Good luck everyone, and have a nice weekend.

4 · Reply

LabPsycho Jun. 13 at 6:41 PM

$CCCC @zawojak IMO, It won't even need a pump - I think it will drift up to close to $2, then retrace, then float up to 2.40...any news from that point could get it close to $3. No pump needed. Good luck.

0 · Reply

zawojak Jun. 13 at 3:47 PM

$CCCC I believe this will pump 250% on a positive news.

0 · Reply

LabPsycho Jun. 13 at 1:08 AM

$CCCC Shown below is the starting point for my (likely World's First) Molecular Dynamic Simulation of C4's CFT8919 drug. Shown is CFT8919 in complex with Cereblon, a component of the CRL4A E3 ubiquitin ligase complex, which can ubiquitinate proteins and target them for degradation and epidermal growth factor receptor (EGFR), mutated forms of which are thought to play a key role in lung and other cancers . Molecular ensemble of the ternary complex shown below is the starting point for the simulations. I am guessing at the structure from the patent C4 & Roche patent (there's zillions of various structure possibilities in the patent) but I think its very close. For artistic and amusement (mostly my own) purposes only.

0 · Reply

jerzypawlik Jun. 12 at 6:39 PM

$CCCC yep ,weak hands got f...k again. It was a time in the morning to buy. I added another 10k. Now is a time to climb back up.

0 · Reply

LabPsycho Jun. 12 at 6:01 PM

$CCCC Stop loses cleaned up / chart backfilled and $CCCC soon to be above $1.72 soon?

0 · Reply

LabPsycho Jun. 12 at 3:35 PM

$CCCC @hk042 Trade volume and price slowly increasing the past several weeks perhaps signals a propitious omen?

1 · Reply

lola269 Jun. 12 at 10:53 AM

$CCCC

0 · Reply

hk042 Jun. 12 at 9:56 AM

$CCCC added some new shares to my long position today. I think soon there will be a catalyst. The promised updates in second half of 2025. I am expecting some news and updates very soon. Good luck peeps!

0 · Reply

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

May 7, 2025, 7:00 AM EDT - 5 weeks ago

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:00 AM EST - 3 months ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 24, 2025, 7:00 AM EST - 4 months ago

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Dec 8, 2024, 12:30 PM EST - 6 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Nov 20, 2024, 7:00 AM EST - 7 months ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Oct 28, 2024, 4:01 PM EDT - 8 months ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 15, 2024, 4:01 PM EDT - 8 months ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Oct 9, 2024, 7:00 AM EDT - 8 months ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Sep 13, 2024, 10:00 AM EDT - 9 months ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 8, 2024, 6:05 PM EDT - 10 months ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 3, 2024, 7:00 AM EDT - 10 months ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Aug 29, 2024, 7:00 AM EDT - 10 months ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Aug 1, 2024, 7:00 AM EDT - 11 months ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 16, 2024, 4:01 PM EDT - 11 months ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Jul 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

Jun 10, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

May 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

Apr 8, 2024, 8:00 AM EDT - 1 year ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 1 year ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Mar 4, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Feb 22, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Jan 9, 2024, 4:01 PM EST - 1 year ago

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 4, 2024, 4:01 PM EST - 1 year ago

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Jan 4, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

$C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma$

Dec 12, 2023, 4:01 PM EST - 1 year ago

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Dec 12, 2023, 7:00 AM EST - 1 year ago

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

$C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma$

Nov 28, 2023, 7:00 AM EST - 1 year ago

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

Nov 20, 2023, 7:00 AM EST - 1 year ago

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Nov 1, 2023, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Oct 11, 2023, 7:00 AM EDT - 1 year ago

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

Sep 5, 2023, 4:01 PM EDT - 1 year ago

C4 Therapeutics Announces Chief Financial Officer Succession

Aug 8, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jul 15, 2023, 1:58 AM EDT - 2 years ago

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 5, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

Jun 20, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

May 30, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

May 4, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Apr 19, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Feb 23, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Feb 8, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at Two Virtual February 2023 Conferences

Jan 30, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

Jan 9, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 3, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 3, 2022, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Sep 29, 2022, 7:00 AM EDT - 2 years ago

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

Sep 26, 2022, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022

Aug 4, 2022, 8:00 AM EDT - 3 years ago

C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Aug 2, 2022, 8:00 AM EDT - 3 years ago

C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D.

LabPsycho Jun. 16 at 2:22 PM

0 · Reply

jerzypawlik Jun. 13 at 9:22 PM

4 · Reply

LabPsycho Jun. 13 at 6:41 PM

0 · Reply

zawojak Jun. 13 at 3:47 PM

$CCCC I believe this will pump 250% on a positive news.

0 · Reply

LabPsycho Jun. 13 at 1:08 AM

0 · Reply

jerzypawlik Jun. 12 at 6:39 PM

$CCCC yep ,weak hands got f...k again. It was a time in the morning to buy. I added another 10k. Now is a time to climb back up.

0 · Reply

LabPsycho Jun. 12 at 6:01 PM

$CCCC Stop loses cleaned up / chart backfilled and $CCCC soon to be above $1.72 soon?

0 · Reply

LabPsycho Jun. 12 at 3:35 PM

$CCCC @hk042 Trade volume and price slowly increasing the past several weeks perhaps signals a propitious omen?

1 · Reply

lola269 Jun. 12 at 10:53 AM

$CCCC

0 · Reply

hk042 Jun. 12 at 9:56 AM

0 · Reply

jerzypawlik Jun. 11 at 9:47 PM

$CCCC I'm loading over 70k shares already. My goal is 100k shares.

1 · Reply

vu_jade Jun. 10 at 6:56 PM

$CCCC bought

0 · Reply

LabPsycho Jun. 10 at 12:44 AM

$CCCC I am guessing at a lot here based on literature and patent searches, so right now in its unrefined state - the image below showing my creation is more of an artistic rendition than an atomically accurate molecular ensemble of cereblon + CFT8919 + EGFR, but I think it is a reasonable first approximation. Enjoy the view!

1 · Reply

Winning_calls Jun. 9 at 3:37 AM

$CCCC pick me up @ $1.75

0 · Reply

zawojak Jun. 8 at 8:00 AM

$CCCC Some bloke on other measage board reckons this will go to the moon soon and can reach $7-8, he seem knowledgeable but who knows.

1 · Reply

Will2ride1 Jun. 8 at 3:09 AM

$CCCC I like it...taking some

1 · Reply

LabPsycho Jun. 6 at 8:28 PM

$HOWL $CCCC Both boards are unusually quite IMO, suggesting to me both are going higher soon

0 · Reply

LabPsycho Jun. 6 at 5:42 PM

$CADL Predicted the drip down from $9 to 4.5 in April, predicted the rebound occurring now last month and predicted there would not be any share buying by Dr. T. I'd like to say I know what he was or wasnt going to do before he did but I am guessing he knew all along he would not buy - and so did I. Yet not a single poster here can acknowledge that - instead they bash with nonsense name calling comments. Looks like LabPsycho’s Artificial Artificial Intelligence (A.^2 I.) ™ is now getting close to 90% accuraty. (recent examples the past ~ month - $XLO down, CADL, $HOWL $TNGX and $CCCC up for example). I keep telling myself its all just a fluke...nothing to do with hundreds of hours of entering parameters, novel algorithms and simulations on Google's GPU supercomputer.

1 · Reply

LabPsycho Jun. 6 at 3:53 PM

$CCCC Up 20 cents on no news and modest volume suggests to me most sellers have been sucked out over the past year, and possibly little resistance to the upside.

0 · Reply

zawojak Jun. 6 at 3:46 PM

$CCCC today is

0 · Reply

Athra24 Jun. 6 at 3:10 PM

$CCCC anybody watching still?

0 · Reply

LabPsycho Jun. 6 at 2:17 PM

$CCCC IMO, it I think this could float up to $1.85 in the next 10 days or so (on no news) to get more in line with other biotechs. Expecially considering $CCCC is: *** still trading ~ 1/2 cash; *** has several milestones expected over the next 3-6 months; *** the 3 month chart is looking good; *** $CCCC has more products in developments and collaborators that comparable biotechs that have risen recently (that now have greater market caps, but less 'stuff' than CCCC, and many with a lot less cash.

1 · Reply

Market Cap	119.29M
Revenue (ttm)	35.58M
Net Income (ttm)	-105.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-296.01%
Debt to Equity Ratio	0.00

Volume	988,400
Avg Vol	1,158,566
Day's Range	N/A - N/A
Shares Out	71.01M
Stochastic %K	79%
Beta	2.93
Analysts	Sell
Price Target	$14.36